Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.36 |
| ▸ | PNP | P00491 | 3/20 | 0.35 |
| ▸ | TYMS | P04818 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321755 | 0.76 | — | — | |
| SCHEMBL14216214 | 0.72 | — | — | |
| SCHEMBL6777122 | 0.72 | CYP3A4 (0.55) | HCAR2CYP3A4BLM | |
| SCHEMBL18312845 | 0.68 | — | — | |
| SCHEMBL10664400 | 0.68 | NUDT1 (0.40) | PNPCYP3A4BLMABL1RIN1 | |
| SCHEMBL5021587 | 0.68 | L3MBTL1 (0.50) | PNPGRIN2CCYP3A4BLMABL1 | |
| SCHEMBL5060580 | 0.68 | SMN1; SMN2 (0.41) | PNPTYMSGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5124123 | 0.68 | PKM (0.41) | PNPKDM4ELMNA | |
| SCHEMBL785286 | 0.65 | SMN1; SMN2 (0.48) | HCAR2KDM4ELMNAHSD17B10 | |
| SCHEMBL15117765 | 0.64 | LMNA (0.44) | PNPGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114445-A1 | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-19 | — | — | US | disclosed |
| WO-2003011297-A1 | N3-SUBSTITUTED 6-ANILINOPYRIMIDINES AND METHODS TO TREAT GRAM-POSITIVE BACTERIAL AND MYCOPLASMAL INFECTIONS | UNIVERSITY OF MASSACHUSETTS (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114445-A1 | N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections | MPHOSPH6, MRPS18A, PNP | EHMT2 4127/4885HCAR2 4461/4885PNP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.